FR2966348A1 - COMPOSITIONS COMPRISING A WRINKLE FILLING MEDIUM AND A CHEMICALLY MODIFIED TETRACYCLINE - Google Patents

Abstract

The invention relates to a combination product comprising: - a composition A comprising at least one wrinkle filler, and - a composition B comprising at least one chemically modified tetracycline, for the treatment of skin aging and scars, the compositions A and B being used simultaneously, separated or spread over time. The invention also relates to a single pharmaceutical composition comprising, in the same physiologically acceptable medium, at least one wrinkle filler and at least one chemically modified tetracycline.

Description

Compositions comprising a wrinkle filler and a chemically modified tetracycline

The present invention relates to compositions for topical and / or parenteral application comprising, in a physiologically acceptable medium, at least one wrinkle filler and at least one chemically modified tetracycline. The invention also relates to the use of these compositions in particular for treating cutaneous aging, in particular for treating by filling wrinkles, fine lines, fibroblastic depletions, dehydration of the skin and any scarring.

The aging of the skin is one of the most visible changes in the senescence process. In addition, the skin is exposed to many factors that can accelerate this physiological process.

There are two different types of skin aging. On the one hand, intrinsic (or physiological) aging, which is more easily evaluated on skin areas that are normally not exposed to the sun and, on the other hand, extrinsic aging, caused by the interaction of environmental factors , especially UV rays. These environmental factors have a much greater effect on sun-exposed body parts, especially in light-skinned people. We also speak of actinic aging. Other factors such as eating habits, smoking, excessive alcohol consumption, chronic diseases and dysfunctions of the endocrine glands also contribute to this aging.

During the intrinsic aging of the skin, the stratum corneum is little modified. The epidermis is atrophic and the dermal-epidermal junction is flattened, so that adhesion to the dermis is less good, facilitating the formation of bubbles. The thickness of the dermis is significantly reduced; there are fewer blood vessels. There are also fewer fibroblasts and their biosynthesis and proliferation abilities are diminished. The elastic fibers undergo modifications first, and then disappear. As far as extrinsic aging is concerned, there is an irregular epidermis, sometimes atrophic, sometimes hyperplastic, with signs of disorganization and dysplasia. Melanocytes are more numerous in some places, and fewer in number. There is also an irregular distribution of melanin in the epidermis, following problems of melanosome transfer. The number of Langerhans cells decreases. The small blood vessels are first dilated, then thin and atrophy.

Wrinkles are the most visible signs of aging. We can distinguish it from several natures, in particular superficial and deep wrinkles. Deep wrinkles are due to dermo-hypodermic changes, while superficial wrinkles could be explained by dermal and possibly epidermal changes. Wrinkles are mainly due to the loss of elasticity of the skin. The collagen present in the dermis fragments, and this fragmentation leads to a loss of structural integrity as well as dysfunctions of fibroblasts (Fisher et al, Looking older, Arch Dermatol., 2008; 144 (5): 666-672). Achievement of the elastic subepidermal network gives rise to a superficial laxity of the aged skin and a folding of its surface. The destruction of elastic fibers in the reticular dermis is responsible for the loss of elasticity and the ability of the skin to regain its shape after stretching. Depending on the type, intensity and topography of the wrinkles, a suitable treatment will be possible.

The skin contains 20% of all the water in the human body and 70% of the skin's water is concentrated in the dermis. It plays a fundamental role by participating in the mechanical properties of the dermis and physiological functioning of the skin, including the integrity of the skin barrier. Synthesized by fibroblasts and keratinocytes, hyaluronic acid is a major constituent of the extracellular matrix that has an important structural function that makes it one of the key elements in maintaining the skin density and thus the firmness of the skin. . It is also a real water sponge essential to maintain hydration. The synthesis and quality of hyaluronic acid decreases with the years causing dehydration, sagging and loss of firmness of the skin. It is therefore essential to maintain a good level of skin hydration, in order to limit the aging of the skin.

Some scars are pathological, among which are hollow scars and raised scars. Depressed scars are hypotrophic scars that can be unsightly, especially when they touch the face in the case of acne scars. The treatment of unsightly skin changes related to aging and scars has made tremendous progress in recent years. A relatively large number of natural or synthetic substances have already been described as dermal implants, that is to say as substances injected directly into the skin, in order to remedy the skin changes resulting from aging. , trauma or disease. Such therapeutic techniques include the local injection of botulinum toxin inactivated (BotoxO) or the use of laser techniques. These different treatments are not exclusive and their combination has even been recommended. Currently, many dermal implants are used but none has yet been considered ideal for safe and healthy tissue augmentation (Naoum C, Dasiou-Plakida D. Dermal filler materials and botulin toxin Int J Dermatol 2001 Oct 40 (10): 609-21).

Moreover, many side effects of these implants have been observed, such as hematomas, erythema, edema (which can occur quickly, i.e. in the day or the week following the application of the product); infections and inflammations (semi-delayed side effects, occurring within 1 to 3 weeks after application of the product); or allergies or pigmentations of the skin in response to the product. In fact, the inflammation triggered by the administration of these implants activates the immune system, in particular through the activation of macrophages, resulting in the release of certain mediators and free radicals that promote the degradation of the implants.

In view of the above, a problem to be solved by the invention is to provide compositions for effectively treating cutaneous aging, and while substantially reducing the side effects resulting directly or indirectly from the induction of the skin. inflammatory reaction and increasing the durability of the filler by reducing the degradation processes directly related to the inflammatory reaction or related to the activation of enzymes involved in the process of degradation of the extracellular matrix (metalloprotease, protease, collagenase, elastase in particular).

The present invention makes it possible to prevent and treat cutaneous aging, in particular wrinkles and fine lines, with improved efficacy and significantly reduced side effects. The present invention thus relates to the specific association of at least one wrinkle filler and at least one chemically modified tetracycline. Such an association makes it possible to treat skin aging and scars, in particular by filling, in an efficient and safe manner.

The invention therefore firstly relates to a combination product comprising: a composition A comprising at least one wrinkle-filler, and a composition B comprising at least one chemically modified tetracycline for the treatment of cutaneous aging and scars, compositions A and B being used simultaneously, separated or spread over time. By "simultaneous" is meant simultaneous application of the filler and chemically modified tetracycline. By "separate way" is meant the subsequent application of either composition within a short time interval (i.e. less than or equal to 1 hour) of the filler and chemically modified tetracycline. By "spread over time" means a consecutive application of the one and the other composition in a longer time interval (ie greater than 1 h and up to 1 month20 after the injection of the product of filling), filling material and chemically modified tetracycline.

The wrinkle filler can then be administered to a subject independently, as is the case for composition A of the combination product. In this case, the wrinkle filler is included in a separate composition (composition A of the combination product), which can be administered simultaneously or in a different time than that of the administration of the composition B comprising the chemically modified tetracycline. Composition A comprising the wrinkle-filling product may be administered topically or parenterally, for example by injection. Preferably, composition A is administered by injection. Composition B of the combination product, including chemically modified tetracycline, may be administered topically, parenterally or orally. Preferably, composition B is administered by injection or topically. Preferably, composition A is in the form of an injectable solution and composition B is suitable for injection or topical application. When the compositions A and B are each in the form of injectable solution, they can be administered by simultaneous co-injection, in particular by means of a double syringe, or by injection of each solution one after the other. The combination product is preferably used for the treatment of cutaneous aging, and more preferentially for the treatment of wrinkles and fine lines.

The invention also relates to a single pharmaceutical composition, especially for topical and / or parenteral application comprising, in the same physiologically acceptable medium, at least one wrinkle filler, and at least one chemically modified tetracycline.

By physiologically acceptable medium is meant a medium compatible with the skin, mucous membranes and / or integuments. The filler may further contain another active ingredient, such as anesthetic such as lidocaine. The pharmaceutical composition is intended for the treatment of cutaneous aging and scars.

Preferably, the pharmaceutical composition is intended for the treatment of wrinkles and fine lines.

Skin aging is more particularly intended to mean wrinkles, fine lines, fibroblastic depletions and dehydration of the skin.

This single pharmaceutical composition can be administered topically or parenterally, for example by injection. Preferably, this single pharmaceutical composition is administered by injection. Preferably, this unique pharmaceutical composition is administered through a syringe.

The present invention also relates to a kit comprising: at least one wrinkle filler, and at least one chemically modified tetracycline.

Preferably, the kit according to the invention comprises a first composition A comprising at least the wrinkle filler, and a second composition B, distinct from the first, comprising the chemically modified tetracycline. The two compositions obtained can be packaged together or separately.

The invention also relates to the combination of at least one wrinkle filler and at least one chemically modified tetracycline for use in the treatment of skin aging and scars.

The combination product or the single pharmaceutical composition according to the invention comprises at least one wrinkle filler.

By filler of wrinkles (or "filler" in English) is any product which, when applied in particular by injection under the skin, allows to smooth it. The consistency of said product is therefore more or less thick depending on the depth of the hollow to be filled.

Said wrinkle-filling product is especially chosen from collagen and its derivatives, hyaluronic acid, its salts and derivatives, alginates, synthetic polymers, elastin, biological polymers and mixtures thereof. Preferably, the wrinkle-filling product is chosen from collagen of human origin, collagen of porcine origin, collagen of bovine origin, crosslinked collagens, hyaluronic acid, its salts and derivatives, lactic acid polymers, methacrylate derivatives, calcium phosphate derivatives, polyacrylamides, polyurethanes, polyalkylimide gels, polyvinyl microspheres, silicones, silica (SiO 2) polymers, biological polymers and the like. their mixtures.

Collagen is a fibrous protein, about 300 kDa, constituting the connective tissue in the animal kingdom. It can be of human or non-human origin, in particular of porcine or bovine origin. Collagen derivatives include, inter alia, crosslinked collagens. Collagen and its derivatives may optionally be mixed with anesthetic, such as lidocaine. Collagen-based wrinkle-filling products and its derivatives are in particular the products: Inamed / Allergan's CosmodermO and CosmoplastO, which are purified human collagens mixed with lidocaine; ZydermO and ZyplastO from Inamed / Allergan, which are highly purified bovine collagens mixed with lidocaine; or - EvolenceO from ColBar, which is composed of porcine cross-linked collagen.

The wrinkle-filling product may also be an alginate or its salts. Among the alginates that may be used, mention may be made of sodium alginate, or else crosslinked alginates, such as the Novabelo product from Merz Aesthetics.

The wrinkle filler may also be a synthetic polymer. By synthetic polymer is meant a system formed by a set of macromolecules of the same chemical nature, resulting from the covalent linking of a large number of identical or different monomeric units of synthetic origin, prepared by polymerization of monomeric molecules. Preferably, said synthetic polymer is chosen from lactic acid polymers such as poly-L-lactic acid, methacrylate derivatives such as hydroxyethyl methacrylate (HEMA), ethyl methacrylate (EMA) and polymethyl methacrylate (PMMA). ), calcium phosphate derivatives such as hydroxylapatite or tricalcium phosphate, polyacrylamides, polyurethanes, polyalkylimide gels, polyvinyl microspheres, silicones, silica polymers (SiO2), and mixtures thereof.

Synthetic polymer-based wrinkle-filling products include the following products: Dermik SculptraO, which is a synthetic lactic acid polymer; - ArtifillO or ArtecollO from Actes Medical, which is a mixture of PMMA, bovine collagen and lidocaine; - RadiesseO from BioForm, which is calcium hydroxyapatite; Beta-Alteano from Stiefel which is tricalcium phosphate; Bio-AlcamidO from SkinRx Distribution Inc. which is a polyalkylimide gel or else EvolutionO from Procytech SA which is polyvinyl microspheres or else AquamidO from Ferrosan A / S / Contura which is a polyacrylamide gel.

The wrinkle filler may also be a biological polymer. By biological polymer is meant a system formed by a set of macromolecules of the same chemical nature, resulting from the covalent linking of a large number of identical or different monomeric units of natural or artificial origin (obtained by chemical modification of a natural polymer). Preferably, said biological polymer is chosen from polymers of methylcellulose, agarose, dextran or chitosan. Organic polymer-based wrinkle-filling products include: - Reviderm IntraO from Rofil Medical International which is a dextran polymer.

More preferably, the wrinkle filler is chosen from hyaluronic acid, a pharmaceutically acceptable salt or a derivative, particularly a sodium or potassium salt. Hyaluronic acid can be used in various forms: a salt, a derivative such as an ester or an amide, in linear or crosslinked form. In particular, the molecular weight is conventionally between 500 kDa and 5000 kDa and the degree of crosslinking depends on the use and the place of application, especially in the field of wrinkles. Hyaluronic acid is a ubiquitous natural polysaccharide that exists in the same form from the simplest bacterium to humans. It is a polysaccharide composed alternately of D-glucuronic acid and N-acetylglucosamine, linked together by alternating glycoside bonds beta-1,4 and beta-1,3. According to Saari H et al. In this study, the polymers of this repeating unit can have a size between 10 and 104 kDa in vivo, and can be used in vivo. hyaluronic acid taken from the umbilical cord with a weight of 2500 kDa.

Hyaluronic acid is a natural constituent of the dermis where it plays an important role in the hydration and elasticity of the skin. However, it decreases in quantity and quality with age, resulting in drying of the skin that wrinkles. It is highly water soluble and forms high viscosity solutions in water. The tolerance of hyaluronic acid is very good and no immunogenicity has been associated with this substance.

Hyaluronic acid may be of human or non-human origin, such as, for example, of avian or bacterial origin.

The term "pharmaceutically acceptable salt" is intended to mean a basic or acidic salt such as, for example, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate or ascorbate salts. , succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate, p-toluenesulfonate and pamoate (ie, 1,1'-methylene-bis- (2-hydroxy-3) naphthoate)), aluminum salts, calcium, lithium, magnesium, potassium, sodium, zinc, or diethanolamine. Certain compounds according to the invention can form pharmaceutically acceptable salts with various amino acids (BERGE ET AL, 66 J. PHARM SCI 1-19 (1977)).

Hyaluronic acid can also be combined with at least one dextran to slow down its degradation in vivo. Wrinkle filler products based on hyaluronic acid and its derivatives are in particular the products: 35 8 Restylane® and Perlane® from Q-Med, or Juvéderme from Allergan / Comeal, or Prevelle Silk® from Genzyme, which are hyaluronic acids of Streptococcus bacteria; Hylaform®, Hylaform Plus® or Captique® from Genzyme / Allergan, which are chemically modified avian hyaluronic acids; Anika's Elevess®, which is composed of hyaluronic acid from Streptococcus bacteria mixed with lidocaine; or Matridex® from TBMC Aesthetics, which is a gel made of hyaluronic acid combined with dextran beads (DEAE Sephadex).

The combination product or the single pharmaceutical composition according to the invention also comprises at least one chemically modified tetracycline. Tetracycline is an antibiotic of the following formula: HO CH3 H3C., CH3 NH2 The carbon numbering on the nucleus of tetracycline is as follows: By chemically modified tetracycline is meant any compound obtained by modifying the various radicals grafted on the nucleus tetracycline, and especially on carbons 2 and / or 4 to 9, and which has anti-inflammatory activity but no antibacterial activity. For example, a modified tetracycline is obtained by modifying the -OH radical of the carbon 6; the -CONH2 radical of carbon 2; the -CH3 radical of the carbon 6 and / or the N (CH3) 2 radical of the carbon 4, but also any hydrogen atom present on the ring.

Modified tetracyclines which can be used according to the invention are described in US Pat. No. 7,211,267. Such tetracyclines have the structure of the natural tetracycline, in which the radicals grafted on carbons 4 to 9, and possibly on carbon 2, have been modified.

The chemically modified tetracyclines (or CMTs in English) are preferably the compounds chosen from 4-dedimethylamino tetracycline (COL-1), tetracycline nitrile (COL-2), 4-dedimethylamino sancycline (COL-3), 4 -dimethylamino chlorotetracycline (COL-4), tetracycline pyrazole (COL-5), 4-dedimethylamino-4-hydroxytetracycline (COL-6), 12a-dehydroxy-4-dimethylaminotetracycline (COL-7), 4-dedimethylamino doxycycline (COL-8), 1-deoxy-12a-dehydroxy-4-dimethylamino tetracycline (COL-9), 4-dedimethylamino minocycline (COL-10), 4-dedimethylamino sancycline derivatives (COL-3) derivatives of 4-dedimethylamino doxycycline (COL-8) and 4-dedimethylamino minocycline derivatives (COL-10).

4-Dodimethylamino sancycline (COL-3) has the formula as described above, in which the radicals -OH and -CH 3 grafted on the same carbon in position 6, as well as the group -N (CH 3) 2 on the carbon in position 4, are substituted by hydrogen atoms. The 4-dedimethylamino sancycline (COL-3) derivatives correspond to the formula of COL-3, in which one or more hydrogen atoms located on the 7 and / or 9 carbons are substituted by selected atoms or groups among: - halogen atoms, preferably bromine; the nitro radical (-NO2); the acetamido radical; the amino radical (-NH 2); the radical -N (CH3) 2, grafted on a different carbon atom at the 4-position; the radical (CH3) 2NC (O) NH-; and the radical CH3 (CH2) 14C (O) NH-. The 4-dedimethylamino sancycline (COL-3) derivatives are preferably the compounds 7-bromo-COL-3 (COL-301), 7-nitro-COL-3 (COL-302), 9-nitro-COL -3 (COL-303), 7-acetamido-COL-3 (COL-304), 9-acetamido-COL-3 (COL-305), 9-dimethylamino-COL-3 (COL-306), 7-amino -COL-3 (COL-307), 9-amino-COL-3 (COL-308), 9-dimethylaminoacetamido-COL-3 (COL-309), 7-dimethylamino-COL-3 (COL-310) or 9 -palmitamide-COL-3 (COL-311).

4-Dodymethylamino doxycycline (COL-8) has the formula as described above, in which the -OH radical grafted on the carbon in the 6-position, as well as the -N (CH 3) 2 group on the carbon in the 4-position , are substituted by hydrogen atoms; and the carbon at the 5-position is substituted with an -OH group. The 4-dedimethylamino doxycycline (COL-8) derivatives correspond to the formula of COL-8, in which one or more hydrogen atoms located on the 9 and / or 2 carbons are substituted with groups chosen from: the nitro radical (-NO2); the acetamido radical; the amino radical (-NH 2); the radical -N (CH3) 2, grafted on a different carbon atom at the 4-position; the radical (CH3) 2NC (O) NH-; and the radical CH3 (CH2) 14C (O) NH-.

The 4-dedimethylamino doxycycline (COL-8) derivatives also include those compounds for which the -CONH 2 radical of the 2-carbon is substituted with the -C (O) NHCH 2 -pyrrolidine radical. The 4-dedimethylamino doxycycline (COL-8) derivatives are preferably the compounds 9-acetamido-COL-8 (COL-801), 9-dimethylaminoacetamido-COL-8 (COL-802), 9-palmitamide-COL- 8 (COL-803), 9-nitro-COL-8 (COL-804), 9-amino-COL-8 (COL-805), 9-dimethylamino-COL-8 (COL-806) and COL-807.

The 4-dimethylamino minocycline (COL-10) has the formula as described above, in which the -OH and -CH3 radicals grafted on the carbon in position 6, as well as the group -N (CH3) 2 on carbon in position 4, are substituted by hydrogen atoms; and the carbon at position 7 is substituted with a group -N (CH3) 2. The 4-dedimethylamino minocycline (COL-10) derivatives correspond to the formula of COL-10, in which the hydrogen atom located on the carbon in position 9 is substituted by a group chosen from: - the nitro radical ( -NO2); and the amino radical (-NH 2). The 4-dimethylamino minocycline (COL-10) derivatives are preferably the 9-amino-COL-10 compound (COL-1002).

In all the above denominations, the prefix "COL" can indifferently be replaced by "CMT".

Preferably, the chemically modified tetracyclines have, in addition to the anti-inflammatory activity, an anti-metalloprotease (MMP or matrix metalloprotease) activity and / or an anti-protease activity or an anti-collagenase activity. Preferentially they are therefore chosen from 4-dedimethylamino sancycline (COL-3), 4-dedimethylamino doxycycline (COL-8), 4-dedimethylamino minocycline (COL-10), 9-acetamido-COL-8 (COL. 801), 9-dimethylaminoacetamido-4-dimethylamino doxycycline (COL-802), 9-nitro-4-dimethylamino-doxycycline (COL-804), 9-amino-4-dimethylamino-doxycycline (COL-805), 9-dimethylamino-4 -dimethylamino sancycline (COL-306), 9-amino-4-dimethylamino sancycline (COL-308), 9-palmitamide-4-dimethylamino sancycline (COL-311) and 9-amino-4-dimethylamino minocycline (COL-1002 ).

In the present description, and unless otherwise specified, it is understood that compositions according to the invention are understood to mean compositions A and B or the single pharmaceutical compositions containing both the filling product of the wrinkles and chemically modified tetracycline.

In the compositions according to the invention, the wrinkle-filling product and the chemically modified tetracycline are respectively present in proportions ranging from 0.001% to 10% by weight relative to the total weight of the composition, preferably from 0.1% to 5% weight of wrinkle-filling product relative to the total weight of the composition and from 0.01% to 5% of chemically modified tetracycline by weight relative to the total weight of the composition.

In the present description, and unless otherwise specified, it is understood that when concentration ranges are given, they include the upper and lower limits of said range.

In known manner, the compositions according to the invention may also contain the usual adjuvants well known to those skilled in the art.

By topical means an external application on the skin or mucous membranes. Topically, the compositions may be in any dosage form normally used for topical administration. By way of nonlimiting example of topical compositions, mention may be made of compositions in liquid, pasty or solid form and, more particularly, in the form of ointments, of aqueous, hydroalcoholic or oily solutions, of dispersions of the type possibly two-phase lotions, serums, aqueous, anhydrous or lipophilic gels, powders, soaked swabs, syndets, wipes, sprays, foams, sticks, compresses, washing bases, emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O / W) or conversely (W / O), a microemulsion, suspensions or emulsions of soft, semi-liquid or solid consistency of the cream type or ointment, suspensions of microspheres or nanospheres or lipid or polymeric vesicles, or microcapsules, microparticles or nanoparticles or polymeric or gelled patches for controlled release.

Parenteral means subcutaneous or intradermal application. By way of nonlimiting examples of parenteral compositions, mention may be made of compositions in the form of solutions or suspensions for infusion or for injection. Parenterally, the compositions can be administered by conventional syringes or double syringes (where two compositions are separated from each other by a sealed membrane, and where mixing is done at the syringe outlet). In the context of combined administration of the wrinkle filler and chemically modified tetracycline according to the invention, the administration frequencies may be identical or different. Advantageously in the context of the invention, the frequency of administration of the composition A injected in the form of an injectable solution can vary from 4 to 24 months, preferably from 4 to 16 months, while those of composition B according to the invention, administered topically, for example in cream form, may vary from 1 to 30 days, preferably from 1 to 7 days.

The invention also relates to the use of at least one wrinkle filler and at least one chemically modified tetracycline, preferably a single pharmaceutical composition as described above or a combination product, for the manufacture of a pharmaceutical composition for the treatment of cutaneous aging and scars.

The composition according to the invention is suitable for the treatment of wrinkled and / or aged skin, and aims in particular to reduce the effects thereof. The treatment of wrinkles, fine lines, fibroblastic depletions, dehydration of the skin and all scars is done by filling. The composition according to the invention can be applied to the skin of the face and the body. In particular, the composition according to the invention can be applied to the areas of the face or forehead marked by expression lines or scars, inter alia due to acne.

The invention also relates to the use of at least one wrinkle filler and at least one chemically modified tetracycline, preferably a single pharmaceutical composition as described above or a combination product, for the manufacture of a pharmaceutical composition for use in reconstructive surgery.

Claims (15)

REVENDICATIONS1. Combination product comprising: - a composition A comprising at least one wrinkle filler, and - a composition B comprising at least one chemically modified tetracycline, for the treatment of cutaneous aging and scars, the compositions A and B being used from simultaneously, separated or spread over time. 2. Combination product according to claim 1, for the treatment of cutaneous aging. 3. Combination product according to claim 1 or 2, characterized in that the composition A is in the form of injectable solution and the composition B is suitable for topical application. 15 4. Combination product according to claim 1, characterized in that composition A and composition B are in the form of injectable solution. 5. A single pharmaceutical composition comprising, in a same physiologically acceptable medium, at least one wrinkle filler and at least one chemically modified tetracycline. 6. Combination product according to one of claims 1 to 4 or composition according to claim 5, characterized in that the wrinkle filler is selected from collagen and its derivatives, hyaluronic acid, its salts and its derivatives, alginates and salts thereof, synthetic polymers, elastin, biological polymers and mixtures thereof. 25 7. Combination product according to one of claims 1 to 4 or 6 or composition according to claim 5 or 6, characterized in that the wrinkle filler is selected from collagen of human origin, collagen of porcine origin collagen of bovine origin, crosslinked collagens, hyaluronic acid and its derivatives, alginate salts, crosslinked alginates, lactic acid polymers, methacrylate derivatives, calcium phosphate derivatives, polyacrylamides, polyurethanes, polyalkylimide gels, polyvinyl microspheres, silicones, silica polymers (SiO2), polymers of methylcellulose, agarose, dextran or chitosan, and mixtures thereof. 8. Combination product according to one of claims 1 to 4, 6 or 7, or composition according to one of claims 5 to 7, characterized in that the chemically modified tetracycline corresponds to any compound obtained by modifying the various radicals grafted onto the nucleus of tetracycline, and exhibiting anti-inflammatory activity. . 20 9. Combination product according to one of claims 1 to 4 or 6 to 8, or composition according to one of claims 5 to 8, characterized in that the chemically modified tetracycline is selected from 4-dedimethylamino tetracycline, tetracycline nitrile, 4-dimethylamino sancycline, 4-dimethylamino chlorotetracycline, tetracycline pyrazole, 4-dimethylamino-4-hydroxytetracycline, 12a-dehydroxy-4-dimethylaminotetracycline, 4-dimethylaminoxyxycin, 1-deoxy-12a-dehydroxy 4-dimethylamino tetracycline, 4-dimethylamino minocycline, 4-dedimethylamino sancycline derivatives, 4-dedimethylamino doxycycline derivatives and 4-dedimethylamino minocycline derivatives. 10. Combination product according to one of claims 1 to 4, or 6 to 9, or composition according to one of claims 5 to 9, characterized in that the chemically modified tetracycline has at least one anti-metalloprotease activity (MMP ). 11. Combination product according to one of claims 1 to 4 or 6 to 10, or composition according to one of claims 5 to Io, characterized in that the chemically modified tetracycline is chosen from 4-dedimethylamino sancycline, the 4- dedimethylamino doxycycline, 4-dimethylamino minocycline, 9-acetamido-4-dedimethylamino doxycycline, 9-dimethylaminoacetamido-4-dimethylaminoxycycline, 9-nitro-4-dimethylaminoxyxycycline, 9-amino-4-dimethylaminooxxycycline, 9-dimethylamino-4 dedimethylamino sancycline, 9-amino-4-dimethylamino sancycline, 9-palmitamide-4-dimethylamino sancycline and 9-amino-4-dimethylamino minocycline. 12. Composition according to one of claims 5 to 11 for its use for treating skin aging. 13. Combination product according to one of claims 1 to 4 or 6 to 11, or composition according to one of claims 5 to 12, characterized in that the treatment of skin aging includes the treatment of wrinkles, fine lines, depletions. fibroblasts and dehydration of the skin. 30 14. Kit comprising: - a first composition A comprising at least the wrinkle filler, and - a second composition B, distinct from the first, comprising the chemically modified tetracycline 15. Combination of at least one wrinkle filler and at least one chemically modified tetracycline for use in the treatment of skin aging and scars.